Updated:
International Infusion
Infusion 51a is an impact-focused investment fund on a mission to invest in, develop, and advance world-changing innovation. Initially, it seeks disruptive...
International Infusion
Infusion 51a is an impact-focused investment fund on a mission to invest in, develop, and advance world-changing innovation. Initially, it seeks disruptive precision-based opportunities within the life sciences. Nestled in the heart of the US research triangle in North Carolina, it is dedicated to fostering the advancement of groundbreaking health solutions worldwide. Since 2015, the fund has been allocating both financial and human capital into vetted opportunities with the potential to disrupt the life-science ecosystem.
General information
Firm type
Generalist
Year founded
2009
Location
Region
North America
Country
United States
City
Research Triangle
Corporate office
Chicago, IL, United States
Principals
Jeff Stephens
General Partner
Scott VanderMeer
MBA, General Partner
Chirag Patel
Director of Technology
Brett Logan
JD, Securities Counsel
Krishn Patel
Director of Data Collection
Todd Smith
MBA, Chief Commercial Officer
Monica Coleman
CPA, Finance Consultant
Mehrab Ajalli
Director of Strategic Growth in the MENA Region
Sector focus
Frequently asked questions
What investment stages does International Infusion target?
The firm's strategy covers seed and early-stage venture, expansion and late-stage growth, management buyouts, PIPEs, recapitalizations, reorganizations, and turnarounds. It also pursues pre-IPO and private-to-public hybrid transactions. This lifecycle-agnostic approach is unusual — most managers specialize in either venture or distressed, but International Infusion operates across both extremes.
Is International Infusion a venture capital firm or a private equity firm?
It is neither exclusively. The firm's mandate includes venture, growth, buyouts, and distressed situations, making it closer to a hybrid or merchant-banking model. Its inclusion of PIPEs, restructurings, and pre-IPO hybrids places it outside conventional fund categories.
Who runs investment decisions at International Infusion?
No named principals are currently in the public record. The firm maintains a deliberately low profile, and no individuals have been identified through official filings, press coverage, or the firm's limited web presence.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: